Skip to main content
Signal8
Launch Terminal

Lexeo Therapeutics, Inc. (LXEO)

Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Lexeo Therapeutics, Inc. Common Stock logo

Lexeo Therapeutics, Inc. Common Stock

NASDAQ:LXEOHealthcare
+2.61%$3.14
AH$3.14+0.00%vs close
Mkt Cap-
Float81.79M
O/S-
Vol
$ Vol
RVOL
Inst Own-
Earnings
Dilution
Lexeo Therapeutics, Inc. Common Stock logoNASDAQ:LXEO$3.14+2.61%
Phase Distribution
8 lead-sponsored trials·7 active·1 completed
Phase 11
Phase 1/23
Phase 21
Not applicable3
Status Overview
Recruiting4
Active, not recruiting3
Completed1

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
Phase
  • Phase 2
    Recruiting

    Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy

    LX2006, Usual Care

    Friedreich Ataxia, Cardiomyopathy, Secondary

    Enrollment
    26
    Start
    Jun 2026
    Primary Completion
    Jun 2032est.
    Completion
    Jun 2032est.
    NCT07721025
  • Phase 1/2
    Completed

    Gene Therapy for APOE4 Homozygote of Alzheimer's Disease

    LX1001

    Alzheimer Disease, Early Onset Alzheimer Disease

    Enrollment
    15
    Start
    Nov 2019
    Primary Completion
    Nov 2024
    Completion
    Nov 2024
    NCT03634007
  • Phase 1/2
    Active, not recruiting

    Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia

    Low dose LX2006, Mid Dose LX2006

    Friedreich Ataxia, Cardiomyopathy, Secondary

    Enrollment
    8
    Start
    Aug 2022
    Primary Completion
    Sep 2029est.
    Completion
    Sep 2029est.
    NCT05445323
  • Phase 1/2
    Active, not recruiting

    Gene Therapy for ACM Due to a PKP2 Pathogenic Variant

    LX2020

    Arrhythmogenic Cardiomyopathy, PKP2-ACM +1

    Enrollment
    10
    Start
    Feb 2024
    Primary Completion
    Dec 2026est.
    Completion
    Mar 2027est.
    NCT06109181
  • Phase 1
    Active, not recruiting

    Long-Term Follow-up of Gene Therapy for APOE4 Homozygote Alzheimer's Disease

    LX1001

    Alzheimer Disease

    Enrollment
    10
    Start
    May 2023
    Primary Completion
    Nov 2028est.
    Completion
    Nov 2028est.
    NCT05400330
  • Observational
    Recruiting

    Clinical Course Of Disease In Participants With FA-CM

    -

    Friedreich Ataxia, Cardiomyopathy

    Enrollment
    65
    Start
    Sep 2025
    Primary Completion
    Sep 2027est.
    Completion
    Sep 2027est.
    NCT06865482
  • Observational
    Recruiting

    A Study to Assess Real-world Patient Characteristics and Clinical Course for Symptomatic Patients With PKP2-ACM

    -

    Arrhythmogenic Cardiomyopathy, PKP2-ACM +1

    Enrollment
    40
    Start
    Jan 2024
    Primary Completion
    Jul 2027est.
    Completion
    Sep 2027est.
    NCT06976606
  • Observational
    Enrolling by invitation

    Long-term Follow-up Study of Gene Therapy for Arrhythmogenic Cardiomyopathy Due to a Plakophilin-2 Pathogenic Variant

    -

    Arrhythmogenic Cardiomyopathy, PKP2-ACM +1

    Enrollment
    10
    Start
    Aug 2025
    Primary Completion
    Aug 2030est.
    Completion
    Aug 2030est.
    NCT07050160
Search ClinicalTrials.gov for “Lexeo Therapeutics”